Impura of Amino Acidum propter synthesize dapibus
Product Detail
| NO | Productus | Cas non | Key species indicator | |||
| Pudicitia | Max. inmunditia | Summa solvent residuum | Humor | |||
| 1 | FMOC-β-Ala-Ala | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 2 | Fmoc-D-Ala-D-Ala | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 3 | Fmoc-β-Ala-D-Ala | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 4 | Fmoc, Arg (PBF) -arg (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 5 | Fmoc-β-ala, Arg (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 6 | Fmoc-D-Arg (PBF) -D-Arg (PBF) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 7 | Fmoc-β-ala-d-Arg (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 8 | Fmoc, homoarg (PBF) -homoarg (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 9 | Fmoc-β-ala-homoarg (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 10 | FMOC, ASN (TT) -asn (TT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 11 | FMOC-β-Ala, ASN (TT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 12 | Fmoc-ASP (otbu) -asp (otbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 13 | Fmoc-β-ala-ASP (otbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 14 | FMOC-CYS (TT) -CYS (TT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 15 | Fmoc-β-ala-cys (TRT) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 16 | Fmoc-CYS (ACM) -cys (ACM) -HH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 17 | FMOC-β-Ala-CYS (ACM) -HH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 18 | Fmoc, GLN (TT) -GLN (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 19 | Fmoc-β-ala-gln (TRT) -HH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 20 | Fmoc, glu (otbu) -glu (otbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 21 | Fmoc-β-ala-glu (otbu) -oh.h2o | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 22 | Fmoc-β-ala-Gly-O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 23 | FMOC-eius (TRT) -his (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 24 | Fmoc-β-ala-eius (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 25 | FMOC-ile-ile-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 26 | Fmoc-β-ala-ile, oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 27 | FMOC-Leu-Leu-O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 28 | Fmoc-β-ala-leu-o | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 29 | Fmoc-D-Leu-D-Leu-O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 30 | Fmoc-β-ala-d-leu-o | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 31 | Fmoc, Lys (Boc) -Lys (Boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 32 | Fmoc-β-ala-lys (Boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 33 | Fmoc, Lys (Alloc) -Lys (Alloc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 34 | Fmoc-β-ala-lys (Alloc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 35 | Fmoc-occurrit-occurrit, O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 36 | Fmoc-β-ala-occurrit, O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 37 | FMOC-Orn (Boc) -orn (Boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 38 | Fmoc-β-ala-bot (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 39 | Fmoc-Phe-Phe-O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 40 | FMOC-β-Ala-Phe-O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 41 | Fmoc-D-Phe-D-Phe-O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 42 | Fmoc-β-ala-d-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 43 | FMOC-Pro-Pro-O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 44 | Fmoc-β-Ala-pro-O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 45 | Fmoc, Ser (TBU), -Ser (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 46 | Fmoc-β-Ala, Ser (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 47 | Fmoc, Ser (TT) -ser (TT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 48 | Fmoc-β-ala-ser (TT) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 49 | Fmoc, Thr (TBU) -Thr (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 50 | Fmoc-β-ala-thr (TBU) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 51 | Fmoc-TRP (Boc) -Trp (Boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 52 | Fmoc-β-ala-TUP (Boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 53 | Fmoc-D-TRP (Boc) -D-TRP (Boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 54 | Fmoc-β-ala-d-TRP (Boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 55 | Fmoc-Tyr (TBU) -yr (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 56 | Fmoc-β-ala-Tyr (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 57 | Fmoc-D-Tyr (et) -D-Tyr (et) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 58 | Fmoc-β-ala-d-Tyr (et) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 59 | Fmoc-Tyr (mihi) -yr (mihi) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 60 | Fmoc-β-ala-Tyr (mihi) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 61 | Fmoc-Val-Val-O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 62 | Fmoc-β-Ala-Val-O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 63 | Fmoc-D-CIT-D-CIT OH O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 64 | Fmoc-β-ala-d-cit-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 65 | Fmoc-β-ala-dab-o | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 66 | FMOC- (3 (II-Naphthyl) -D-Ala) II-O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 67 | Fmoc-β-ala-3- (II-naphthyl) -d-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 68 | Fmoc- (3 (III-Pyridinyl) -D-Ala) II-O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 69 | Fmoc-β-ala-3- (III-Pyridyl) -D-Ala | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 70 | FMOC- (IV-Chloro-D-PHE) II-O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 71 | FMOC-β-ALA-IV-Chloro-D-Phe-O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 72 | Fmoc- (D-4aph (TBUCBM)) II-O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 73 | Fmoc-β-ala-D-4aph (TBUCBM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 74 | FMOC-APH (L-Hor) -aph (l-Hor) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 75 | Fmoc-β-ala-APH (l-Hor) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 76 | Fmoc, Lys (Ipr, Boc) -Lys (Ipr, Boc) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 77 | Fmoc-β-ala-lys (Ipr, boc) -ohh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 78 | Fmoc-β-ala-aeea, o | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 79 | FMOC-AIB-AIB-O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 80 | FMOC-β-AL-aib-O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 81 | FMOC, Arg, O | 91000-69-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 82 | H-Arg (PBF) -OH | 200115-86-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 83 | Fmoc-D-Arg, O | 130752-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 84 | HD-Arg (PBF) -OH | 200116-81-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 85 | Fmoc, homoarg, oh.hcl | 208174-14-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 86 | H-Homoarg (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 87 | Fmoc-D-homoarg-O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 88 | HD-homoarg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 89 | FMOC-ASN, O | 71989-16-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 90 | H-ASN (TT) -OH | 13388-58-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 91 | FMOC-ASP-O | 119062-05-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 92 | H-ASP (otbu) -oh | 3057-74-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 93 | FMOC-CYS-O | 135248-89-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 94 | H-CYS (TT) -OH | 2799/7/7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 95 | H-CYS (ACM) -H.HCL | 28798-28-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 96 | FMOC-GLN, O | 71989-20-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 97 | H-GlN (TT) -OH | 102747-84-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 98 | Fmoc, glu-O | 121343-82-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 99 | H-Glu (otbu) -oh.h2o | 2419-56-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| C | Fmoc, sua-o | 116611-64-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CI | H-eius (TT) -OH | 35146-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CII | Boc, sua-o | 17791-52-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CIII | Fmoc, lys-o | 105047-45-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CIV | H-lys (Boc) -oh | 2418-95-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CV | H-Lys (Alloc) -oh | 6298/3/9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CVI | FMOC-bot, oh.hcl | 201046-57-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CVII | H-Orn (Boc) -oh | 13650-49-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CVIII | Fmoc, Ser-O | 73724-45-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CIX | H-Ser (TBU) -OH | 18822-58-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CX | H-Ser (TT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CXI | Fmoc-Threh2o thre-thr | 73731-37-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CXII | H, Th (TBU) -OH | 4378-13-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CXIII | Fmoc-TRP-O | 35737-15-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CXIV | H-TRP (Boc) -oh | 146645-63-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CXV | Fmoc-D-TRP, O | 86123-11-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CXVI | HD-TRP (Boc) -oh | 201290-11-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CXVII | FMOC-Tyranni, O | 92954-90-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CXVIII | H-Tyr (TBU) -OH | 18822-59-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CXIX | Fmoc-D-Tyranni, O | 112883-29-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CXX | HD-Tyr (et) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CXXI | H-Tyr (mihi) -oh.hcl | 67423-43-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CXXII | Fmoc-D-4aph (CBM) -OH | 324017-22-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CXXIII | HD-4aph (TBUCBM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CXXIV | Fmoc, lys (Ipr) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| CXXV | H, lys (Ipr, Boc) -ohh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
De
Compensatio
GENOLEX providere magni qualitas products, si aliqua uber qualis est elevatur a client in requiritur tempus frame cum sufficientibus, nos providere necessaria analysis et iudicium ad trigger procedendi de ultricies et iudicium.
Productio
In capacitates of pharmaceutical products pervenit tons gradus, in capacitates eget products semoto 100tons + gradu, in capabilities sunt bene instructi servire clients worldwide.
Investigationis et progressionem
Omni anno, ibi est consilium extruxerat per R & D dolor ut develop diversis products, cum peltas posuit, omnis membrum in quadrigis erit ad portare in cum KPI responsibility et in incitamentum consilium.
